Literature DB >> 20434465

The flexible mind is associated with the catechol-O-methyltransferase (COMT) Val158Met polymorphism: evidence for a role of dopamine in the control of task-switching.

Lorenza S Colzato1, Florian Waszak, Sander Nieuwenhuis, Danielle Posthuma, Bernhard Hommel.   

Abstract

Genetic variability related to the catechol-O-methyltransferase (COMT) gene (Val158Met polymorphism) has received increasing attention as a possible modulator of cognitive control functions. Recent evidence suggests that the Val158Met genotype may differentially affect cognitive stability and flexibility, in such a way that Val/Val homozygous individuals (who possess low prefrontal dopamine levels) may show more pronounced cognitive flexibility than Met/-carriers (who possess high prefrontal dopamine levels). To test this, healthy humans (n=87), genotyped for the Val158Met polymorphism at the COMT gene, performed a task-switching paradigm, which provides a relatively diagnostic index of cognitive flexibility. As predicted, Met/-carriers showed larger switching costs (i.e., less cognitive flexibility), F(1,85)=4.28, p<0.05, than Val/Val homozygous individuals. Our findings support the idea that low prefrontal dopamine levels promote cognitive flexibility. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434465     DOI: 10.1016/j.neuropsychologia.2010.04.023

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  50 in total

1.  Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients.

Authors:  Weidong Ji; Ning Li; Kang Ju; Hong Zheng; Chuang Yang; Ping Xu; Silu Chen; Aiai Cao; Xue Chen; Lanting Guo
Journal:  Neurol Sci       Date:  2014-11-04       Impact factor: 3.307

2.  The roles of COMT val158met status and aviation expertise in flight simulator performance and cognitive ability.

Authors:  Q Kennedy; J L Taylor; A Noda; M Adamson; G M Murphy; J M Zeitzer; J A Yesavage
Journal:  Behav Genet       Date:  2010-12-31       Impact factor: 2.805

3.  Effect of the COMT Val158Met genotype on lateral prefrontal activations in young children.

Authors:  Yusuke Moriguchi; Ikuko Shinohara
Journal:  Dev Sci       Date:  2018-01-04

4.  A neurogenetics approach to defining differential susceptibility to institutional care.

Authors:  Zoe H Brett; Margaret Sheridan; Kate Humphreys; Anna Smyke; Mary Margaret Gleason; Nathan Fox; Charles Zeanah; Charles Nelson; Stacy Drury
Journal:  Int J Behav Dev       Date:  2015-03

5.  Dopaminergic Genetic Polymorphisms Predict Rule-based Category Learning.

Authors:  Kaileigh A Byrne; Tyler Davis; Darrell A Worthy
Journal:  J Cogn Neurosci       Date:  2016-02-26       Impact factor: 3.225

Review 6.  A matched filter hypothesis for cognitive control.

Authors:  Evangelia G Chrysikou; Matthew J Weber; Sharon L Thompson-Schill
Journal:  Neuropsychologia       Date:  2013-11-05       Impact factor: 3.139

7.  Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs.

Authors:  M Falcone; C Jepson; P Sanborn; J N Cappella; C Lerman; A A Strasser
Journal:  Genes Brain Behav       Date:  2011-10-06       Impact factor: 3.449

8.  Becoming a balanced, proficient bilingual: Predictions from age of acquisition & genetic background.

Authors:  Kelly A Vaughn; Arturo E Hernandez
Journal:  J Neurolinguistics       Date:  2018-01-05       Impact factor: 1.710

Review 9.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.